Regulation of adaptive immunity; the role of interleukin-10
Since the discovery of interleukin-10 (IL-10) in the 1980s, a large body of work has led to its
recognition as a pleiotropic immunomodulatory cytokine that affects both the innate and …
recognition as a pleiotropic immunomodulatory cytokine that affects both the innate and …
Mechanism of immunopotentiation and safety of aluminum adjuvants
H HogenEsch - Frontiers in immunology, 2013 - frontiersin.org
Aluminum-containing adjuvants are widely used in preventive vaccines against infectious
diseases and in preparations for allergy immunotherapy. The mechanism by which they …
diseases and in preparations for allergy immunotherapy. The mechanism by which they …
Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets
JF Ryan, R Hovde, J Glanville, SC Lyu… - Proceedings of the …, 2016 - National Acad Sciences
Allergen immunotherapy can desensitize even subjects with potentially lethal allergies, but
the changes induced in T cells that underpin successful immunotherapy remain poorly …
the changes induced in T cells that underpin successful immunotherapy remain poorly …
T cells in the control of organ-specific autoimmunity
JA Bluestone, H Bour-Jordan, M Cheng… - The Journal of …, 2015 - Am Soc Clin Investig
Immune tolerance is critical to the avoidance of unwarranted immune responses against self
antigens. Multiple, non-redundant checkpoints are in place to prevent such potentially …
antigens. Multiple, non-redundant checkpoints are in place to prevent such potentially …
Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of …
E Shardlow, M Mold, C Exley - Allergy, Asthma & Clinical Immunology, 2018 - Springer
Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only
two aluminium salts which are used in clinically-approved vaccines, Alhydrogel® and …
two aluminium salts which are used in clinically-approved vaccines, Alhydrogel® and …
Standardizing T-cell biomarkers in type 1 diabetes: challenges and recent advances
S Ahmed, K Cerosaletti, E James, SA Long… - Diabetes, 2019 - Am Diabetes Assoc
Type 1 diabetes (T1D) results from the progressive destruction of pancreatic β-cells in a
process mediated primarily by T lymphocytes. The T1D research community has made …
process mediated primarily by T lymphocytes. The T1D research community has made …
Immunological GABAergic interactions and therapeutic applications in autoimmune diseases
GJ Prud'homme, Y Glinka, Q Wang - Autoimmunity reviews, 2015 - Elsevier
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain.
However, it is also produced in other sites; notably by pancreatic β cells and immune cells …
However, it is also produced in other sites; notably by pancreatic β cells and immune cells …
Vaccine against autoimmune disease: antigen-specific immunotherapy
RP Anderson, B Jabri - Current opinion in immunology, 2013 - Elsevier
Recent interest in testing whether the success of antigen-specific immunotherapy (ASIT) for
autoimmune diseases in mice can be translated to humans has highlighted the need for …
autoimmune diseases in mice can be translated to humans has highlighted the need for …
Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for …
H Elding Larsson, M Lundgren, B Jonsdottir… - Pediatric …, 2018 - Wiley Online Library
Objective Treatments have failed to delay or stop the autoimmune process, preceding onset
of type 1 diabetes. We investigated if autoantigen‐specific treatment with alum‐formulated …
of type 1 diabetes. We investigated if autoantigen‐specific treatment with alum‐formulated …
Immune mechanisms and pathways targeted in type 1 diabetes
LM Jacobsen, BN Newby, DJ Perry, AL Posgai… - Current diabetes …, 2018 - Springer
Abstract Purpose of Review The immunosuppressive agent cyclosporine was first reported
to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 …
to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 …